Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.73 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.48 |
| ▸ | UBE2N | P61088 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.75 |
| ▸ | CA12 | O43570 | 5/20 | 0.73 |
| ▸ | CA6 | P23280 | 5/20 | 0.73 |
| ▸ | CA7 | P43166 | 5/20 | 0.73 |
| ▸ | CA9 | Q16790 | 5/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.73 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.73 |
| ▸ | CA4 | P22748 | 4/20 | 0.73 |
| ▸ | CA5A | P35218 | 4/20 | 0.73 |
| ▸ | CA3 | P07451 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | RECQL | P46063 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6251707 | 0.96 | CA12 (0.79) | UBE2NMAPTPMP22CA12CA6 | |
| SCHEMBL6658738 | 0.96 | CA12 (0.79) | UBE2NMAPTPMP22CA12CA6 | |
| Hydrochloric Acid SCHEMBL3673346 | 0.96 | UBE2N (0.80) | UBE2NMAPTPMP22CA12CA6 | |
| SCHEMBL7712115 | 0.96 | CA12 (0.79) | UBE2NMAPTPMP22CA12CA6 | |
| SCHEMBL11808474 | 0.93 | CA12 (0.79) | UBE2NMAPTPMP22CA12CA6 | |
| SCHEMBL9720429 | 0.93 | CA12 (0.79) | UBE2NMAPTPMP22CA12CA6 | |
| SCHEMBL26667 | 0.93 | CA12 (0.85) | UBE2NMAPTPMP22CA12CA6 | |
| SCHEMBL18784646 | 0.90 | CA12 (0.81) | UBE2NMAPTPMP22CA12CA6 | |
| SCHEMBL15306482 | 0.90 | CA12 (0.81) | UBE2NMAPTPMP22CA12CA6 | |
| Hydrochloric Acid SCHEMBL8021183 | 0.90 | UBE2N (0.93) | UBE2NMAPTPMP22CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979681-B2 | Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer | UNIVERSITY COURT, THE UNIVERSITY OF EDINBURGH (GB) | 2005-12-27 | — | — | US | disclosed |
| US-20050239765-A1 | Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer | UNIVERSITY COURT, THE UNIVERSITY OF EDINBURGH, A UNITED KINGDOM CORPORATION | 2005-10-27 | — | — | US | disclosed |
| EP-1224192-B1 | HALF-SANDWICH RUTHENIUM (II) COMPOUNDS COMPRISING NITROGEN CONTAINING LIGANDS FOR TREATMENT OF CANCER | UNIV COURT THE UNIVERSITY OF E (GB) | 2005-08-31 | — | — | EP | disclosed |
| US-6936634-B2 | Ruthenium (II) compounds for use in the therapy of cancer | THE UNIVERSITY COURT, THE UNIVERSITY OF EDINBURGH (UK) (GB) | 2005-08-30 | — | — | US | disclosed |
| US-20040220166-A1 | Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands ligands for treatment of cancer | University Court | 2004-11-04 | — | — | US | disclosed |
| EP-1294732-B1 | RUTHENIUM (II) COMPOUNDS FOR USE IN THE THERAPY OF CANCER | UNIV EDINBURGH (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-6750251-B2 | TO PRODUCE MEDICAMENT FOR THERAPY AND PROPHYLAXIS OF CANCER | THE UNIVERSITY COURT, THE UNIVERSITY OF EDINBURGH (UK) (GB) | 2004-06-15 | — | — | US | disclosed |
| US-20040029852-A1 | Ruthenium (ii) compounds for use in the therepy of cancer | UNIVERSITY COURT, THE UNIVERSITY OF EDINBURGH, THE (GB) | 2004-02-12 | — | — | US | disclosed |
| EP-1294732-A1 | RUTHENIUM (II) COMPOUNDS FOR USE IN THE THERAPY OF CANCER | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2003-03-26 | — | — | EP | disclosed |
| US-20030023088-A1 | Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer | UNIVERSITY COURT, THE UNIVERSITY OF EDINBURGH (UK), THE (GB) | 2003-01-30 | — | — | US | disclosed |
| EP-1224192-A1 | HALF-SANDWICH RUTHENIUM (II) COMPOUNDS COMPRISING NITROGEN CONTAINING LIGANDS FOR TREATMENT OF CANCER | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH OF OLD COLLEGE (GB) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002002572-A1 | RUTHENIUM (II) COMPOUNDS FOR USE IN THE THERAPY OF CANCER | THE UNIVERSITY COURT, THE UNIVERSITY OF EDINBURGH (GB) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001030790-A1 | HALF-SANDWICH RUTHENIUM (II) COMPOUNDS COMPRISING NITROGEN CONTAINING LIGANDS FOR TREATMENT OF CANCER | THE UNIVERSITY COURT, THE UNIVERSITY OF EDINBURGH (GB) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239765-A1 | Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer | NR0B1, NR0B2, NCOR1 | CA2 3015/4885ESR1 257/4885UBE2N 1408/4885 |
| US-20030023088-A1 | Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer | NR0B1, CBR1, NR0B2 | CA2 3134/4885ESR1 976/4885UBE2N 2762/4885 |
| US-20040220166-A1 | Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands ligands for treatment of cancer | NR0B1, NR0B2, NR4A1 | CA2 3567/4885ESR1 860/4885UBE2N 2843/4885 |
| US-20040029852-A1 | Ruthenium (ii) compounds for use in the therepy of cancer | BRCA1, NFE2L2, RBBP7 | CA2 1451/4885ESR1 449/4885UBE2N 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.